Previous 10 | Next 10 |
Health Catalyst, Inc. (HCAT) Q3 2022 Earnings Conference Call November 08, 2022, 05:00 PM ET Company Participants Adam Brown - Senior Vice President-Finance and Investor Relations Daniel Burton - Chief Executive Officer Bryan Hunt - Chief Financial Officer ...
Health Catalyst press release ( NASDAQ: HCAT ): Q3 Non-GAAP EPS of -$0.13 beats by $0.06 . Revenue of $68.35M (+10.7% Y/Y) beats by $1.56M . Q4 revenue expected to be between $66.9 million and $68.9 million, vs. consensus of $66.79M. FY22 revenue between $2...
SALT LAKE CITY, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2022. ...
Summary Having suffered through a sharp decline in earnings multiples, small cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings ...
Summary The market is greatly overestimating the effect of higher rates and inflation on durable goods, materials and financial companies, while underestimating the impact on speculative assets. The Strategy underperformed its Russell 2000 benchmark, as positive contributions from...
SALT LAKE CITY, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its third quarter 2022 operating results on Tuesday, November 8, 2022, after ...
Health Catalyst, Inc. ( NASDAQ: HCAT ) dropped ~7% pre-market Tuesday after RBC Capital Markets lowered its rating on the healthcare software company and lowered its price target to $9 from $19 per share in reaction to challenges faced by the hospital industry. Hospi...
Summary Health Catalyst has been on my "Bio Boom" watch list for a couple of years, but the valuation has stopped me from starting a position. The market-wide sell-off has brought the share price down to an acceptable valuation to allow me to finally find a spot for HCAT in my Com...
Health Catalyst Reveals Catalyst Awards Winners Recognizing World-Class Healthcare Improvements PR Newswire SALT LAKE CITY , Sept. 14, 2022 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analyt...
Health Catalyst ( NASDAQ: HCAT ) announced three new leadership appointments in support of its strategic focus. It includes the appointment of the company's current Chief Revenue Officer, Kevin Freeman, as Chief Growth Officer, and current Chief Brand and Communications O...
News, Short Squeeze, Breakout and More Instantly...
Health Catalyst Announces New Credit Facility for up to $225,000,000 PR Newswire SALT LAKE CITY , July 18, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst" or the "Company") (Nasdaq: HCAT), a leading provider of data and analytics technology and...
2024-07-01 07:30:03 ET Wells Fargo analyst issues OVERWEIGHT recommendation for HCAT on July 1, 2024 06:12AM ET. The previous analyst recommendation was Overweight. HCAT was trading at $6.39 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...